Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions.

##STR00001##

The present disclosure relates to, inter alia, a modified surface comprising an optically active monomer, a polymeric material having a surface onto which the optically active monomer is covalently bound. In one aspect, a membrane comprising an optically active monomer, a poly(aryl sulfone) membrane having a surface onto which the optically active monomer is covalently bound. The present disclosure also relates to a method of modifying a surface, the method comprising applying sufficient energy to a surface to induce covalent bonding with an optically active monomer, and contacting the optically active monomer with the surface. In one aspect, a method of modifying a surface of a poly(aryl sulfone) membrane is disclosed. In another aspect, a method of synthesizing an optically active monomer is disclosed. In one aspect, a method of filtration of chiral compounds is disclosed.

The present disclosure relates to, inter alia, a modified surface comprising an optically active monomer, a polymeric material having a surface onto which the optically active monomer is covalently bound. In one aspect, a membrane comprising an optically active monomer, a poly(aryl sulfone) membrane having a surface onto which the optically active monomer is covalently bound. The present disclosure also relates to a method of modifying a surface, the method comprising applying sufficient energy to a surface to induce covalent bonding with an optically active monomer, and contacting the optically active monomer with the surface. In one aspect, a method of modifying a surface of a poly(aryl sulfone) membrane is disclosed. In another aspect, a method of synthesizing an optically active monomer is disclosed. In one aspect, a method of filtration of chiral compounds is disclosed.

Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)

##STR00001##

and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)

##STR00001##

and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.